Joint Impact of TyG-Related Indices and eGDR on Cardiometabolic Multimorbidity Risk in Chinese Adults: Insights from a Nationwide Cohort
Posted inCardiology Diabetes & Endocrinology news

Joint Impact of TyG-Related Indices and eGDR on Cardiometabolic Multimorbidity Risk in Chinese Adults: Insights from a Nationwide Cohort

This study elucidates that high triglyceride glucose (TyG) related indices combined with low estimated glucose disposal rate (eGDR) synergistically elevate cardiometabolic multimorbidity (CMM) risk in middle-aged and older Chinese adults, enhancing early risk stratification and prevention strategies.
Unveiling Early Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors and Validation of Screening Approaches in the SAIL-RA Cohort
Posted innews Respiratory Rheumatology

Unveiling Early Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors and Validation of Screening Approaches in the SAIL-RA Cohort

This article examines the prevalence, risk factors, and diagnostic screening strategies for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) in early rheumatoid arthritis, highlighting age and disease activity as key predictors and validating practical screening tools.
Monlunabant Hiển Thị Tiềm Năng Giảm Cân Trong Béo Phì và Hội Chứng Chuyển Hóa: Đánh Giá Thử Nghiệm Giai Đoạn 2A
Posted innews

Monlunabant Hiển Thị Tiềm Năng Giảm Cân Trong Béo Phì và Hội Chứng Chuyển Hóa: Đánh Giá Thử Nghiệm Giai Đoạn 2A

Thử nghiệm giai đoạn 2a này cho thấy monlunabant gây ra giảm cân đáng kể ở nhiều liều lượng khác nhau trong nhóm người lớn béo phì mắc hội chứng chuyển hóa, với các tác dụng phụ phụ thuộc vào liều lượng nhấn mạnh sự cần thiết phải đánh giá thêm về độ an toàn.
Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis
Posted inClinical Updates news Oncology Urology

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients ineligible for cisplatin, with manageable safety.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.
Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen
Posted inHematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.
Smoothing the Leap to Adult Care: EU‑CAYAS‑NET Recommendations for Transition of Childhood and Adolescent Cancer Survivors
Posted innews Oncology Pediatrics

Smoothing the Leap to Adult Care: EU‑CAYAS‑NET Recommendations for Transition of Childhood and Adolescent Cancer Survivors

EU‑CAYAS‑NET issues 44 strong, evidence‑based recommendations to standardize and improve transitions from paediatric to adult survivorship care for those diagnosed with cancer at 0–21 years, emphasizing planned transfer, risk‑based follow‑up, care coordination, and patient‑centred supports.